کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
6106466 | 1211161 | 2011 | 13 صفحه PDF | دانلود رایگان |
Atherosclerosis has been described as a liver disease of the heart [1]. The liver is the central regulatory organ of lipid pathways but since dyslipidaemias are major contributors to cardiovascular disease and type 2 diabetes rather than liver disease, research in this area has not been a major focus for hepatologists. Virus-host interaction is a continuous co-evolutionary process [2] involving the host immune system and viral escape mechanisms [3]. One of the strategies HCV has adopted to escape immune clearance and establish persistent infection is to make use of hepatic lipid pathways. This review aims to:
- update the hepatologist on lipid metabolism
- review the evidence that HCV exploits hepatic lipid pathways to its advantage
- discuss approaches to targeting host lipid pathways as adjunctive therapy.
Journal: Journal of Hepatology - Volume 55, Issue 6, December 2011, Pages 1428-1440